In interviews, patients said that they had specifically sought out Zepbound and didn’t want to switch. “I chose Zepbound with my doctor,” said Carl Houde, 49, of Saugus, Mass. “For that to ...

European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...

On Monday, the European Commission approved GSK plc’s (NYSE:GSK) Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients ...

On Monday, the European Commission approved GSK plc’s (NYSE:GSK) Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with ...

Jemperli is indicated: in combination with carboplatin and paclitaxel, for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for ...

Expanded approval includes MMRp/MSS tumours, which represent approximately 75% of endometrial cancer cases; Approval based on RUBY Part 1 trial, which showed a median overall survival (OS) of 44.6 ...

The FDA has approved a new drug for some adult patients with endometrial cancer. Jemperli (dostarlimably) — made by U.K. company GSK — is intended for primary advanced or recurrent disease.

GSK announces US FDA expands Jemperli plus chemotherapy approval to all adult patients with primary advanced or ... 54-67) of patients in the Jemperli plus chemotherapy group compared to 49% (95% CI: ...

At the 2.5-year landmark, the survival rate was higher for patients treated with the Jemperli regimen (61%) versus those who received chemotherapy only (49%).

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: "Jemperli plus chemotherapy is the first and only immuno-oncology regimen to show significant and meaningful improvement ...

This time around, GSK armed Jemperli with data showing it could extend patients’ lives. Jemperli and chemo significantly cut the risk of death by 31% compared with chemo in part 1 of the phase 3 ...

PHILADELPHIA, August 01, 2024--Expanded approval of Jemperli (dostarlimab-gxly) plus chemo in endometrial cancer as first & only IO-based treatment to show overall survival benefit ...